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Abstract
Proteoliposomes purified from the Outer Membrane of Neisseria meningitidis B, have been successfully used as core
for adjuvants and vaccine formulations. We have tried to increase their structural definition and to conserve their
efficacy and stability avoiding the addition of the aluminum hydroxide to the final formulation. Liposomal particle
systems were prepared from components of defined molecular structure, such as a Neisseria meningitidis B protein
complex, extracted and purified without forming vesicle structures. Liposomes were prepared from a mixture of
dioleoyl phosphatidyl serine and cholesterol, using the classical dehydration-rehydration method. Transmission
Electron Microscopy (TEM) was used to characterize the liposomes. BALB/c mice were used for animal testing
procedures. Analysis of specific IgG response, serum bactericidal activity as well as DTH reaction was carried out.
Isolation and purification of mRNA and real-time PCR, was performed to determine the dominating Th lymphokine
pattern. The new antimeningococcal formulation without aluminum hydroxide prepared with components of
defined molecular structure assembled itself into Neoproteoliposomes (NPL) ranging from 50 to 70 nm in
diameter. The extraction and purification of selected membrane proteins to provide the antigen for this new
formulation (PD-Tp), as well as the NPL-formulation favors a Th1 response pattern, suggested by the higher
percentages of DTH, increased expression of proinflamatory lymphokine mRNAs when administered by
intramuscular and intranasal routes. It stimulates a systemic bactericidal antibody response against Neisseria
meningitidis B and immunologic memory similar to the Cuban VA-MENGOC-BC® vaccine, even at lower dosages
and is less reactogenic at the injection site in comparison with the formulation with aluminum hydroxide. This new
adjuvant formulation could be applicable to the development of new and improved vaccines against
meningococcal disease, and eventually as modulators of the immune response against other diseases.
Introduction
Production of serogroup B N. meningitidis membrane pro-
teins into vesicles or proteoliposomes (PL) and their use as
the main antigenic component in the Cuban meningococ-
cal vaccine VA-MENGOC-BC®, has been one of the most
efficient approaches to protect against disease produced
by this serogroup [1,2]. The capacity of PL to activate a
Th1 immune response has been characterized and
includes the production of gamma interferon (gIFN),
induction of delayed hypersensitivity (DTH), opsonopha-
gocytosis and serum bactericidal activity; a mechanism
generally accepted as protective, mediated by IgG2a in
mice and IgG1 and IgG3 in humans [3,4]. This vaccine is
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adjuvanted twice: by the proteoliposomal conformation
adopted by membrane proteins and by aluminum hydro-
xide gel. At present, different adjuvants, based on nano-
particle systems, have been developed to release antigens
in subunit vaccines. Among them liposomes, proteolipo-
somes and other delivery systems have great acceptance,
since they work as non-living antigen vectors [5]. How-
ever, it is necessary to increase molecular definition pre-
serving efficiency and stability, without adding aluminum
hydroxide to the final formulation, thus reducing reacto-
genicity [6]. The aim of the present study was to investi-
gate the immune response and local reactogenicity
induced in BALB/c mice, immunized with an adjuvant for-
mulation prepared from components of the N. meningi-
tides B with defined molecular structure, which are
assembled in the form of proteoliposomes, without adding
aluminum hydroxide gel.
Material and methods
Liposomal particle systems were prepared from a Neisseria
meningitidis B protein complex, extracted and purified
without forming vesicle structures (PD) and assembled in
the form of proteoliposomal nanoparticles designated as
NPL. A buffer suspension of the protein complex (Tris-
HCL 5mM, detergent 0.1%, pH 7.4), named PD-Tp and in
addition the Cuban meningococcal VA-MENGOC-BC®
vaccine, and the OMV (Outer Membrane Vesicles or pro-
teoliposomes) supplied by Finlay Institute, Cuba, were
used as controls. Neoproteoliposomes (NPL) were pre-
pared from a mixture of dioleoyl phosphatidyl serine
(DOPS) and cholesterol (Sigma Aldrich Co.UK), using the
dehydration-rehydration procedure described by Kirby
and Gregoriadis in 1984 [7]. The particulate shape and
size was established by transmission electron microscopy
(TEM) and negative staining was performed using the
classical drop method with 2% (v/v) phosphotungstic acid.
BALB/c mice (10 per group) were distributed in three
immunization groups and a control. The first, second
and third group were immunized with two intramuscular
(IM) doses of NPL, PD-Tp (15 µg in 250µl) respectively
and VA-MENGOC-BC®, (25 µg in 250µl) with a 14 day
interval. The fourth group was immunized with a buffer
solution and was used as a negative control identified as
NC. Two additional groups were immunized with three
intranasal (IN) doses of NPL or OMV (15µg in 25µl,
12.5µl in each nostril) with a 7 day interval. The serum
samples were collected 7, 14, 21 and 60 days after the last
immunization. (Fig.1B) Specific antimeningococcal-
OMV-IgG antibody titers in sera from immunized mice
were determined by a capture enzyme-linked immuno-
sorbent assay (ELISA), according to the Finlay Institute
protocol. Calculations were performed using the CDC
ELISA Data Processing and Analysis Program, Version
2.15-09/27/2004 [8,9]. The serum bactericidal antibody
(SBA) assay was carried out as previously reported [10],
but using a Cu385-83 serogroup B N. meningitidis strain
suspension containing 2x108CFU/mL in phosphate buf-
fered saline (PBS) supplemented with a rabbit comple-
ment (Pel Freez) (with no bactericidal activity in itself).
The bactericidal antibody titer was calculated as the reci-
procal of the highest dilution of serum causing 50% or
more colony death by bacteriolysis compared with count-
ing of CFU in relation to the control sample. The results
were expressed as 1/Titer. Twenty one days after the last
dose the DTH reaction was induced and measured at
48 h after intradermical challenge with PD, in immunized
mice; the footpad swelling test was carried out as pre-
viously described [11]. The determination of cytokine
expression was performed by RT-PCR. Briefly, the spleen
was removed from five animals in each group and the
splenocytes purified. These were cultured in RPMI med-
ium and stimulated with 12μg of the antigen (PD). Total
RNA was extracted from the spleen cells in 1 ml of TRI-
zol® reagent (Invitrogen). Analysis of mRNA expression
was carried out using TaqMan Gene Expression Assays
(Applied Biosystems, Ca., USA) as described previously
[12]. In this method, mRNA levels for each sample were
normalized to glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) levels and then expressed as a relative
increase or decrease compared with the negative control
levels. Each experiment was repeated a minimum of
three times. For in vivo experiments, error bars represent
the mean, plus the SD of the readings from a minimum
of five mice. The significance of the difference between
the means of the control group and the experimental
groups or between two experimental groups is indicated
with an asterisk and was calculated by the non-para-
metric Mann-Whitney test. In all cases, a p< 0.05 signifi-
cance level was used.
Results and discussion
NPL obtained in this work showed homogeneity with
respect to shape and size, ranging from 50 to 70 nm of
mean diameter, making them appropriate for antigen
presentation to the immune system (Fig. 1A). Intramus-
cular administration of the NPL formulation was capable
of inducing specific antimeningococcal-OMV-IgG anti-
body levels in immunized animals, at the same level as
VA-MENGOC-BC®; its concentration was higher and
different from those of the NC group, and from the non
adjuvanted protein PD at 7, 14, 21 days after immuniza-
tion. The subcutaneous footpad inoculation with PD at
21 days, challenging for the DTH assay, resulted in a very
effective booster dose as demonstrated by the antibody
level increase measured at 60 days. Antibody levels in
animals immunized with NPL, VA-MENGOC-BC® and
PD were not significantly different with each other, but
only with those of the NC group.
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These findings confirm the NPL and VA-MENGOC-
BC® capacity for inducing immunological memory, since
all the animals received an intradermal PD booster for the
DTH assay. This reaction allowed in vivo confirmation of
Th1 clone functioning after activation by their capacity to
generate inflammatory processes when faced with a new
antigenic challenge. There did not appear to be any
immediate hypersensitivity reaction, proving that the
inflammatory processes were provoked after 48 hours.
Both NPL and PD-Tp induced higher responses than VA-
MENGOC-BC®, and NC (Fig.1C).
SBA assays using pooled mouse sera from the 21 and 60
day time points after the last dose showed that those ani-
mals immunized with either NPL or VA-MENGOC-BC®,
had the greatest bactericidal activity against the Cu385-83
epidemic strain. The sera from the groups immunized with
the NPL and VA-MENGOC-BC® IM, (titres of 256 ± SD ≤
0.5 log2 at 21 days and titre of 512 ± SD ≤ 0.5 log2 VA-
MENGOC-BC® IM, and titre of 1024 ± SD ≤ 0.5 log2 NPL
at 60 days), the PD-Tp sera at 21 days did not elicit bacter-
icidal titres (SBT), while the bactericidal titre at 60 days
was 8 ± SD ≤ 0.5log2. The IN route of immunization was
Figure 1 Antimeningococcal protectogenic potential and adjuvant capacity of the new proteoliposomic (NPL) formulation from
N. meningitidis serogroup B, without aluminum hydroxide. A: Micrograph obtained by TEM, showing abundant spherical particles of a size
ranging between 50 and 70 nm of diameter. B Diagram showing the scheme of immunization designed for the evaluation of the formulations in
BALB/c mice. In C, the graph represents the mean and SD of the level of specific antibodies expressed in units of IgG anti OMV in the serum of the
immunized mice at 7, 14, 21 and 60 days, after the last dose of immunization, (*) indicate significant differences for p< 0.05. The results of the
determination of the bactericidal activity of serum are shown in D, each bar represents the mean of three individual experiments, accomplished for
each group of assay, at the 21 days after the last immunization dose and at the 60 days after receiving the antigenic intradermical challenge for DTH
assay. NPL: Mice inoculated with the formulation of neo-proteoliposomes, PD-Tp: Mice immunized with the protein complex of the N. meningitidis
serogroup B (PD) in buffer (Tris HCL 5mM, 0.1% detergent, pH 7.4), VA-MENGOC-BC®: Mice inoculated with the Cuban antimeningococcal BC vaccine,
OMV: Mice inoculated with Outer Membrane Vesicles of the N. meningitidis serogroup B, NC: Control group that received buffer solution. IM:
Intramuscular administration route, IN: Intranasal administration route.
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less effective in inducing SBA titer sat this dosage since
NPL only elicited titres of 64 ± SD ≤ 0.5log2 at 21 days and
128 ± SD ≤ 0.5log2 at 60 days while the OMV induced
titres of 8 ± SD ≤ 0.5log2 at 21 days and 16 ± SD ≤ 0.5 log2
at 60 days (Fig.1D).
The SBA is a correlate for protective antibody responses
against Neisseria meningitides. SBA titers above 8 or a 4
fold increase are considered as protective in many species
[10]. We found that IM immunization with NPL and VA-
MENGOC-BC® yielded sera with greater bactericidal
activity than the IN immunized groups with the same for-
mulations. The observed differences between SBA for the
different immunization routes IM vs. IN suggest that com-
position differences exist among antibody production,
which motivated us to perform, in a separate study, an
IgG subclass analysis. We found that those animals immu-
nized IM with the NPL and VA-MENGOC-BC® elicited
higher levels of IgG2a than did those animals immunized
IN at 15 micrograms per dose (results not shown). In
mice, the IgG2a isotype is the most efficient activator of
complement, while the IgG1 isotype is the poorest. Thus,
the lower IgG2a detected in IN treatment could in part
explain the inferior bactericidal activity observed in these
sera. Similar results were obtained by del Campo and cow-
orkers [13] immunizing with OMV and its derivative
cochleates at 50µg dose by the IN route.
Th1/Th2 patterns coexist in the immune response,
but one predominates over the other, depending on the
antigenic stimulation of the pathogen responsible for
the disease and, in the case of vaccines, on the formula-
tion used. The three assay formulations evaluated in this
study stimulate IL-10, TGFb, IFN-g and TNF expres-
sion. These last pro-inflammatory cytokines, related to
cellular response, significantly increase their expression
in the groups vaccinated with PD-Tp and NPL, when
they are administered by the IM, as well as IN route.
Meanwhile the relative amounts of IL-10 and TGFb
messengers are reduced or maintained relatively equal
to with respect to VA-MENGOC-BC®. These last cyto-
kines favor more regulatory pressure on the immune
response pattern.
In relation to these results, the new antimeningococcal
formulation (NPL) without aluminum hydroxide prepared
with components of defined molecular structure, and
assembled in the form of nanoproteoliposomes, are equal
in terms of immunogenicity to the classic formulation that
uses aluminum hydroxide, even at a lower dosage, giving a
more potent T-cell immune response with equivalent
immunological memory, lower reactogenicity and better
structural definition. This new formulation could be
applicable to new vaccines against meningococcal disease,
and eventually as modulators of the immune response
against other diseases.
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